Pegylated liposomal doxorubicin in stage IVB mycosis fungoides

Giuseppe Di Lorenzo, R. Di Trolio, M. Delfino, S. De Placido

Research output: Contribution to journalArticle

Abstract

Background: Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma. Objectives: To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF). Methods: In this retrospective study, we evaluated outcomes and recorded adverse effects in 10 patients with MF (seven men and three women) with extracutaneous involvement. Patients were treated with LD 20 mg m-2 administered intravenously every 4 weeks. Results: All patients received at least two cycles of LD, three patients received four cycles and one patient received six cycles. Three patients (30%) had a partial response and two patients had stable disease. Grade 1-2 leucopenia occurred in three of the 10 patients, and grade 4 leucopenia in one. Three patients had grade 2 palmoplantar erythrodysaesthesia. Conclusions: This study demonstrates that LD is beneficial in terms of activity and toxicity in stage IVB MF. These observations should be verified in larger studies.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalBritish Journal of Dermatology
Volume153
Issue number1
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Mycosis Fungoides
Leukopenia
liposomal doxorubicin
Cutaneous T-Cell Lymphoma
Retrospective Studies

Keywords

  • Advanced disease
  • Chemotherapy
  • Mycosis fungoides
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Dermatology

Cite this

Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. / Di Lorenzo, Giuseppe; Di Trolio, R.; Delfino, M.; De Placido, S.

In: British Journal of Dermatology, Vol. 153, No. 1, 07.2005, p. 183-185.

Research output: Contribution to journalArticle

Di Lorenzo, G, Di Trolio, R, Delfino, M & De Placido, S 2005, 'Pegylated liposomal doxorubicin in stage IVB mycosis fungoides', British Journal of Dermatology, vol. 153, no. 1, pp. 183-185. https://doi.org/10.1111/j.1365-2133.2005.06682.x
Di Lorenzo, Giuseppe ; Di Trolio, R. ; Delfino, M. ; De Placido, S. / Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. In: British Journal of Dermatology. 2005 ; Vol. 153, No. 1. pp. 183-185.
@article{f19d4b5d11d84536ba9d6c44482be525,
title = "Pegylated liposomal doxorubicin in stage IVB mycosis fungoides",
abstract = "Background: Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma. Objectives: To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF). Methods: In this retrospective study, we evaluated outcomes and recorded adverse effects in 10 patients with MF (seven men and three women) with extracutaneous involvement. Patients were treated with LD 20 mg m-2 administered intravenously every 4 weeks. Results: All patients received at least two cycles of LD, three patients received four cycles and one patient received six cycles. Three patients (30{\%}) had a partial response and two patients had stable disease. Grade 1-2 leucopenia occurred in three of the 10 patients, and grade 4 leucopenia in one. Three patients had grade 2 palmoplantar erythrodysaesthesia. Conclusions: This study demonstrates that LD is beneficial in terms of activity and toxicity in stage IVB MF. These observations should be verified in larger studies.",
keywords = "Advanced disease, Chemotherapy, Mycosis fungoides, Pegylated liposomal doxorubicin",
author = "{Di Lorenzo}, Giuseppe and {Di Trolio}, R. and M. Delfino and {De Placido}, S.",
year = "2005",
month = "7",
doi = "10.1111/j.1365-2133.2005.06682.x",
language = "English",
volume = "153",
pages = "183--185",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Pegylated liposomal doxorubicin in stage IVB mycosis fungoides

AU - Di Lorenzo, Giuseppe

AU - Di Trolio, R.

AU - Delfino, M.

AU - De Placido, S.

PY - 2005/7

Y1 - 2005/7

N2 - Background: Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma. Objectives: To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF). Methods: In this retrospective study, we evaluated outcomes and recorded adverse effects in 10 patients with MF (seven men and three women) with extracutaneous involvement. Patients were treated with LD 20 mg m-2 administered intravenously every 4 weeks. Results: All patients received at least two cycles of LD, three patients received four cycles and one patient received six cycles. Three patients (30%) had a partial response and two patients had stable disease. Grade 1-2 leucopenia occurred in three of the 10 patients, and grade 4 leucopenia in one. Three patients had grade 2 palmoplantar erythrodysaesthesia. Conclusions: This study demonstrates that LD is beneficial in terms of activity and toxicity in stage IVB MF. These observations should be verified in larger studies.

AB - Background: Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma. Objectives: To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF). Methods: In this retrospective study, we evaluated outcomes and recorded adverse effects in 10 patients with MF (seven men and three women) with extracutaneous involvement. Patients were treated with LD 20 mg m-2 administered intravenously every 4 weeks. Results: All patients received at least two cycles of LD, three patients received four cycles and one patient received six cycles. Three patients (30%) had a partial response and two patients had stable disease. Grade 1-2 leucopenia occurred in three of the 10 patients, and grade 4 leucopenia in one. Three patients had grade 2 palmoplantar erythrodysaesthesia. Conclusions: This study demonstrates that LD is beneficial in terms of activity and toxicity in stage IVB MF. These observations should be verified in larger studies.

KW - Advanced disease

KW - Chemotherapy

KW - Mycosis fungoides

KW - Pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=22944452432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944452432&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2005.06682.x

DO - 10.1111/j.1365-2133.2005.06682.x

M3 - Article

C2 - 16029347

AN - SCOPUS:22944452432

VL - 153

SP - 183

EP - 185

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 1

ER -